4 free views remaining today

alpha-mannosidosis

Description

Alpha-mannosidosis is a rare genetic disorder characterized by a deficiency of the enzyme alpha-D-mannosidase, which leads to the accumulation of certain complex sugars in the body's cells.

Key Features:

  • Affects many organs and tissues of the body
  • Can cause intellectual disability, distinctive facial features, and skeletal abnormalities
  • Characteristic facial features may include a large head, coarse facial features, and other physical anomalies
  • May also lead to hearing loss, weakened immune system, and cerebellar disorders

Types:

  • The disease is generally broken down into three forms:
    • Mild (type 1): slowly progressive form
    • Moderate (type 2): more severe symptoms than type 1
    • Severe (type 3): often rapidly progressive and potentially life-threatening

Causes:

  • Caused by an autosomal recessive genetic mutation in the gene MAN2B1, located on chromosome 19
  • Results in a deficiency of the enzyme alpha-D-mannosidase, leading to the accumulation of complex sugars in the body's cells

Variability:

  • The clinical phenotype of alpha-mannosidosis varies considerably, with a wide spectrum of clinical findings and broad variability in individual presentation
  • At least three clinical types have been suggested in untreated individuals: mild, moderate, and severe forms.

References: [1] [2] [3] [4] [5] [6] [7] [8] [9]

Additional Characteristics

  • Affects many organs and tissues of the body
  • Can cause intellectual disability, distinctive facial features, and skeletal abnormalities
  • Characteristic facial features may include a large head, coarse facial features, and other physical anomalies
  • May also lead to hearing loss, weakened immune system, and cerebellar disorders
  • The disease is generally broken down into three forms: mild (type 1), moderate (type 2), and severe (type 3)
  • Caused by an autosomal recessive genetic mutation in the gene MAN2B1, located on chromosome 19
  • Results in a deficiency of the enzyme alpha-D-mannosidase, leading to the accumulation of complex sugars in the body's cells
  • The clinical phenotype of alpha-mannosidosis varies considerably, with a wide spectrum of clinical findings and broad variability in individual presentation

Signs and Symptoms

Alpha-Mannosidosis Signs and Symptoms

Alpha-mannosidosis is a progressive, highly heterogeneous disease that affects various aspects of an individual's health. The symptoms can range from mild to severe and vary widely between individuals.

  • Intellectual Disability: Alpha-mannosidosis often leads to intellectual disability, which can be mild to moderate in severity.
  • Hearing Loss: Hearing impairment is a common symptom of alpha-mannosidosis, affecting both children and adults.
  • Ataxia: Ataxia, or loss of coordination and balance, is another symptom associated with this disease.
  • Skeletal Abnormalities: Skeletal abnormalities, such as coarse facial features and dysostosis (abnormal bone development), are also characteristic of alpha-mannosidosis.
  • Immune Deficiency: Individuals with alpha-mannosidosis often have weakened immune systems, making them more susceptible to infections.
  • Cerebellar Disorders: Cerebellar disorders, such as ataxia and dysarthria (speech difficulties), can also occur in individuals with alpha-mannosidosis.

Variability of Symptoms

The symptoms of alpha-mannosidosis can vary widely between individuals, even among siblings who share the same gene variant. The disease represents a spectrum or continuum of severity, making diagnosis challenging and often delayed.

  • Early-Onset Form: In some cases, alpha-mannosidosis can manifest in infancy with rapid progression and severe neurological deterioration.
  • Mild to Moderate Symptoms: Others may experience mild to moderate symptoms that become apparent later in childhood or even adulthood.

Importance of Early Diagnosis

Minimizing the time to diagnosis is crucial in ensuring that individuals with alpha-mannosidosis receive timely medical attention. This can help alleviate some of the symptoms and improve overall quality of life.

References:

  • [1] Alpha-mannosidosis symptoms and diagnosis.
  • [3] The signs and symptoms of alpha-mannosidosis can range from mild to severe.
  • [4] Alpha mannosidosis is a lysosomal storage disorder, a form of inborn metabolic disease.
  • [5] The symptoms, severity, and progression of alpha-mannosidosis vary widely between individuals, making diagnosis challenging and often delayed.

Additional Symptoms

  • Hearing Loss
  • Intellectual Disability
  • Skeletal Abnormalities
  • Immune Deficiency
  • Cerebellar Disorders
  • ataxia

Diagnostic Tests

Diagnostic Tests for Alpha-Mannosidosis

Alpha-mannosidosis is a rare genetic disorder that can be diagnosed through various tests. The diagnostic process typically involves a combination of clinical evaluation, laboratory tests, and genetic analysis.

  • Measurement of α-mannosidase enzyme activity: This is considered the gold standard to confirm a diagnosis of alpha-mannosidosis. The test measures the level of α-mannosidase enzyme activity in white blood cells (leukocytes) or cultured tissue cells (fibroblasts). [1][4]
  • Genetic testing: Genetic testing can be used to confirm a diagnosis of alpha-mannosidosis, especially when the clinical presentation is atypical. Exome sequencing and genome sequencing are commonly used methods for genetic analysis. [2][3]
  • Urine analysis: Urine analysis may also be performed to detect mannose-rich oligosaccharides, which can be indicative of alpha-mannosidosis. However, this test is less frequently used as a diagnostic tool. [9]

Diagnostic Algorithm

A recent proposed diagnostic algorithm for alpha-mannosidosis involves two algorithms: one for patients ≤10 years of age and one for those >10 years of age. These algorithms can aid in early diagnosis and may be applied in various settings. [11]

Specialized Tests

In some cases, a metabolic disease specialist or clinical geneticist may recommend additional tests to confirm the diagnosis of alpha-mannosidosis. These specialists can provide guidance on the most appropriate diagnostic approach for each individual case.

References:

[1] - Context result 1 [2] - Context result 2 [3] - Context result 13 [4] - Context result 5 [9] - Context result 9 [11] - Context result 11

Treatment

Enzyme Replacement Therapy (ERT) for Alpha-Mannosidosis

Alpha-mannosidosis is a rare genetic disorder that affects the body's ability to break down certain sugars, leading to a buildup of toxic substances. While there is no cure for this condition, recent advancements in medical research have led to the development of enzyme replacement therapy (ERT) as a treatment option.

Velmanase Alfa: The First FDA-Approved ERT

In 2023, the U.S. Food and Drug Administration (FDA) approved velmanase alfa (Lamzede), an enzyme replacement therapy specifically designed for the treatment of non-central nervous system manifestations of alpha-mannosidosis [1][2]. This approval marked a significant milestone in the management of this condition.

How ERT Works

Velmanase alfa works by replacing the deficient enzyme, alpha-mannosidase, which is essential for breaking down certain sugars. By supplementing this enzyme, velmanase alfa helps to reduce the accumulation of toxic substances in the body, thereby alleviating some of the symptoms associated with alpha-mannosidosis [3].

Benefits and Limitations

While ERT has shown promise in managing non-central nervous system manifestations of alpha-mannosidosis, it is essential to note that this treatment does not alter the disease course. The primary goal of ERT is to manage symptoms and improve quality of life for patients with this condition [4].

Current Treatment Options

Currently, there are no pharmacological treatments available that can alter the disease course of alpha-mannosidosis. Treatments aim to manage symptoms and prevent complications through a proactive approach [5]. The FDA's approval of velmanase alfa has provided a new treatment option for patients with non-central nervous system manifestations of this condition.

References:

[1] FDA approves Lamzede (velmanase alfa) for the treatment of non-central nervous system manifestations of alpha-mannosidosis. [Context 2]

[2] Velmanase alfa-tycv (trade name: LAMZEDE) is an enzyme replacement therapy approved by the FDA for treatment of non-central nervous system manifestations of alpha-mannosidosis. [Context 4]

[3] Enzyme replacement therapy is at the moment the most effective therapy for lysosomal storage disease, including alpha-mannosidosis. [Context 3]

[4] There are currently no pharmacological treatments for alpha-mannosidosis that alter the disease course. Treatments aim to manage symptoms and prevent complications through a proactive approach. [Context 9]

[5] Disease Management. There is currently no cure for Alpha Mannosidosis, and treatment is often limited to addressing or controlling symptoms. [Context 14]

Recommended Medications

  • Enzyme Replacement Therapy (ERT)
  • Velmanase alfa
  • Lamzede

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Differential Diagnosis of Alpha-Mannosidosis

Alpha-mannosidosis is a rare genetic disorder that can be challenging to diagnose due to its overlapping symptoms with other lysosomal storage diseases. The differential diagnosis of alpha-m

Additional Information

oboInOwl#hasOBONamespace
disease_ontology
rdf-schema#comment
OMIM mapping confirmed by DO. [SN].
oboInOwl#id
DOID:3413
core#notation
DOID:3413
oboInOwl#hasDbXref
UMLS_CUI:C0024748
core#exactMatch
MESH:D008363
IAO_0000115
A lysosomal storage disease that has_material_basis_in deficiency of the alpha-D-manosidase enzyme resulting in the impairment of cell function from a build up of complex sugars derived from glycoproteins in the lysosome.
oboInOwl#hasExactSynonym
deficiency of alpha-mannosidase
rdf-schema#label
alpha-mannosidosis
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#NCIthesaurus
rdf-schema#subClassOf
http://purl.obolibrary.org/obo/DOID_3211
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_10311
owl#annotatedSource
t423045

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.